Strength Training on Pancreatic Cancer (STOPC)

German Cancer Research Center

Status

Withdrawn

Conditions

Myopathy

Cachexia

Pancreatic Neoplasms

Treatments

Behavioral: strength training

Study type

Interventional

Funder types

Other

Identifiers

NCT01395563

GermanCRC

Details and patient eligibility

About

The purpose of this study is to determine whether prednisone, methotrexate, and cyclophosphamide are effective in the treatment of rapidly progressive hearing loss in both ears due to autoimmune inner ear disease (AIED).

Full description

Sudden out-of-hospital cardiac arrest (OOH-CA) remains a significant cause of death, in spite of recent declines in overall mortality from cardiovascular disease. Existing methods of emergency resuscitation are inadequate due to time delays inherent in the transport of a trained responder with defibrillation capabilities to the side of the OOH-CA victim. Existing Emergency Medical Services (EMS) systems typically combine paramedic Emergency Medical Technician (EMT) services with some level of community involvement, such as bystander cardiopulmonary resuscitation (CPR) training. Some communities include automated external defibrillators (AEDs) at isolated sites or in mobile police or fire vehicles. A comprehensive, integrated community approach to treatment with AEDs would have community units served by these volunteer non-medical responders who can quickly identify and treat a patient with OOH-CA. Such an approach is termed Public Access Defibrillation (PAD).

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with pancreatic carcinomas after surgery (resection or exploration)
given consent

Exclusion criteria

acute infection
pain
no mobility or ability for walking or standing
severe neurological disorders (apoplex, morbus Parkinson, paresis of the lower extremeties)
severe cardiac or cardiovascular diseases (z.B. heart insufficiency NYHA III, myocardial infarction <3 months)
rhytmical disorders, that contraindicate ergospirometric examinations
cardiac therapy with digitalis pharmacy
unclear syncopes
severe pulmonal insufficiency
renal insufficiency (GFR < 30% at Krea >3 mg/dl)
synchronous participation in an other clinical trial